Investigation into Florida condo collapse is expected to finish in 2026
More than four years after a Florida condominium collapse killed 98 people , federal investigators have yet to make a final determination of the cause — but they do have some leading theories.
The National Institute of Standards and Technology, the agency handling the probe, said this week it hopes to conclude the investigation in 2026.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
United Therapeutics Announces World's First Bioengineered External Liver Treatment in Clinical Study
United Therapeutics Corporation (NASDAQ:UTHR) is one of the most undervalued US stocks according to analysts. On June 24, United Therapeutics Corporation and Intermountain Health announced a medical breakthrough: the world's first patient treated in a clinical study with a bioengineered external liver assist product called miroliverELAP. This historic procedure marked the first human clinical trial of a manufactured organ alternative and was performed at Intermountain Medical Center in Murray, Utah, by a team led by Christopher J. Danford, MD, who is a transplant hepatologist at Intermountain Health. The patient treated was experiencing liver failure and was not eligible for a liver transplant. A team of scientists in a laboratory, running tests on a biotechnology product. MiroliverELAP was developed by Miromatrix Medical Inc., which is a subsidiary of United Therapeutics and is an external liver assist combination product. It comprises a single-use MIRO-001 bioengineered liver and an extracorporeal blood circuit, designed to provide temporary liver support for patients with acute liver failure/ALF. ALF is a severe condition characterized by a rapid loss of liver function, often in individuals with no prior history of liver disease. United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company that develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases internationally. While we acknowledge the potential of UTHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Bloomberg
an hour ago
- Bloomberg
Odd Lots: The Biotech Start-Up Making Vaccines for Bees and Shrimp
Think of a biotech company and most people will think of a business trying to come up with cures and treatments for human illnesses. There's not a lot of discussion about companies trying to do the same for animals, insects, or even... crustaceans. And yet, healthy animals are a key part of the ecosystem and important for our food supply. In this episode we speak to Annette Kleiser, CEO of Dalan Animal Health, which has developed the world's first vaccine for bees and is now working on a similar treatment to protect shrimp. We talk about the development and regulatory process, plus what it's actually like raising money for a brand new business.
